Renal safety in patients treated with bisphosphonates for osteoporosis: a review. - Wikidata - awgldk - TriplyDB

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

http://www.wikidata.org/entity/Q38125952

about

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research Chronic kidney disease and osteoporosis: evaluation and management.Chronic kidney disease and the skeleton.Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Treatment of osteoporosis in renal insufficiency.Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings.Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease.Ibandronate: A Review in Japanese Patients with Osteoporosis.Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.Bisphosphonate use after clinical fracture and risk of new fracture.Long-Term Oral Toxicity and Anti-osteoporotic Effect of Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal Osteoporosis.

P2860

Q26782621-9B4985EB-A5F2-491B-8A43-8843D003CC17 Q33833414-D8CF6703-BF5E-485A-B2B6-E087384926E0 Q35755179-91A93DF7-1809-4B07-8CD2-712FA9BB5BD6 Q36471074-4D3862C8-A820-4F06-9B37-0E3AD9EC77C7 Q37135281-1549E152-15ED-4129-BC17-C528BE63F9B0 Q38335645-1BD0B081-FA99-4453-B8BC-590704364E9F Q38450329-A8134973-B46A-45C4-BD13-8A1B95889A51 Q38458773-10F70373-125E-4F19-A40D-11F01F15CF15 Q38750001-EE65D1BB-7570-4841-A741-18C96642C994 Q41342134-E0D00B73-3D7E-4321-8972-D8383848E3B2 Q49350663-F5D5F5FC-D00D-4EED-A0A0-87550A6A17E4 Q55193010-8A3CCE4B-FB76-448F-909F-002B94F2CE38

P2860

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

http://www.wikidata.org/entity/Q38125952

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

@en

type

label

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

@en

prefLabel

Renal safety in patients treated with bisphosphonates for osteoporosis: a review.

@en

P1433

Q38125952-7B285080-33A7-4030-A44B-933ADED18D64

P1476

Q38125952-69979D39-0AB0-4C98-AA26-F986E37A2073

P2093

Q38125952-27EDD7CD-1C9C-4CA6-A3F5-C217B5E2D963

Q38125952-44C94D27-92AF-41D5-B8A6-53BDE74F36FF

Q38125952-6311C49E-E6FE-4E41-BB05-FE2A703FDCD3

Q38125952-786C4EE9-C8BE-4C08-944B-94988B9F3B04

P2860

Q38125952-03DCB6DD-FA5B-49D0-90B0-07D81D791CB9

Q38125952-04617007-4426-4409-88CA-0B5048F6E14B

Q38125952-07480D89-8B04-44F6-A3FB-C9B441A199B6

Q38125952-1223F5D1-9EF3-41EB-82F5-A00A6A7FA201

Q38125952-2406E4AB-380F-4696-B9CE-A548C11D4882

Q38125952-29ACD4C6-0577-4388-95D3-A6F6D348F33F

Q38125952-2DFDC59B-1B8E-4D5A-952B-2A742F3F1B3A

Q38125952-2F89BF18-F5C5-445B-934E-AB92B03C7FC3

Q38125952-3AB15BA9-468E-43A2-A2AD-E26D8B9B632F

Q38125952-4555BED3-B442-4216-B1A5-DDB275B711F0

P304

Q38125952-077A07FF-5E86-425B-8594-A96DCC7E419E

P31

Q38125952-CE5E18B7-33A9-4CEB-9B1D-278C49CF6F96

P356

Q38125952-C43A2384-4428-4A9B-B3AA-3BD0026C0F51

P433

Q38125952-243A4048-4430-4C6F-A7C0-E65957048E95

P478

Q38125952-4F6FD519-643D-4F57-8229-B367A2D73161

P50

Q38125952-1E3119B1-E982-46EC-B302-3895FE9454AD

P577

Q38125952-F713CD3A-1F10-4FB2-8910-FBE492D611F1

P5875

Q38125952-FC474F89-83FE-4CB9-87ED-17DE802F2AAE

P698

Q38125952-A922AF77-BA91-4B2D-B601-F9F1DA1F7F2B

P921

Q38125952-882F72F7-879C-4903-8F1D-65658AA06FB4

P356

P1433

Journal of Bone and Mineral Research

P1476

Renal safety in patients treated with bisphosphonates for osteoporosis: a review

@en

P2093

Paul D Miller

http://www.w3.org/2001/XMLSchema#string

Pieter Evenepoel

http://www.w3.org/2001/XMLSchema#string

Sophie A Jamal

http://www.w3.org/2001/XMLSchema#string

Steven Boonen

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

PTH--a particularly tricky hormone: why measure it at all in kidney patients?

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Prediction of creatinine clearance from serum creatinine

Anticancer drug-induced kidney disorders.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Bisphosphonates: the first 40 years.

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

P304

2049-2059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.2058

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Richard Eastell

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

254274309

http://www.w3.org/2001/XMLSchema#string

P698

23907861

http://www.w3.org/2001/XMLSchema#string

P921